1. Home
  2. FMY vs RNTX Comparison

FMY vs RNTX Comparison

Compare FMY & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Trust Motgage Income Fund of Beneficial Interest

FMY

First Trust Motgage Income Fund of Beneficial Interest

SELL

Current Price

$11.08

Market Cap

47.0M

Sector

Finance

ML Signal

SELL

Logo Rein Therapeutics Inc.

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.36

Market Cap

50.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FMY
RNTX
Founded
2005
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.0M
50.9M
IPO Year
2005
2017

Fundamental Metrics

Financial Performance
Metric
FMY
RNTX
Price
$11.08
$0.36
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $6.00
AVG Volume (30 Days)
4.3K
★ 714.3K
Earning Date
01-01-0001
11-16-2026
Dividend Yield
★ 6.98%
N/A
EPS Growth
N/A
★ 44.16
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.67
$0.28
52 Week High
$12.36
$2.10

Technical Indicators

Market Signals
Indicator
FMY
RNTX
Relative Strength Index (RSI) 42.40 24.64
Support Level $10.96 N/A
Resistance Level $11.52 $0.91
Average True Range (ATR) 0.20 0.08
MACD -0.02 -0.02
Stochastic Oscillator 13.71 15.57

Price Performance

Historical Comparison
FMY
RNTX

About FMY First Trust Motgage Income Fund of Beneficial Interest

First Trust Mortgage Income Fund is a United States-based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield, and maturity.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: